Skip to main content
TipRanks
Go Ultimate75% OFF

Acurx Pharmaceuticals (3ZO0) Stock Price & Analysis

1 Followers

3ZO0 Stock Chart & Stats

€5.09€0.00(0.00%)
At close: 5:30 PM GMT+1
€0€50€100Feb 14Oct 19Mar 6Jan 13Jul 18
Day’s Range
EUR 5.09 - EUR 5.20
52-Week Range
EUR 5.09 - EUR 5.20
Previous Close
EUR 5.09
Volume
N/A
Average Volume (3M)
0
Market Cap
EUR 5.69M
Enterprise Value
-EUR 2.96M
Total Cash (Recent Filing)
EUR 9.65M
Total Debt (Recent Filing)
EUR 0
Price to Earnings (P/E)
―
Beta
-1.54
Next Earnings
Mar 18, 2027 (Est.)
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Clinical Development Progress

Enrollment in the fully funded PATHFINDER trial advances ibezapolstat toward pivotal evidence in recurrent CDI. FDA openness to a pre-NDA discussion creates a defined regulatory path, while successful data could support approval discussions across acute and recurrent infection settings.

Differentiated Antibiotic Profile

The reported bactericidal activity, toxin reduction, and activity against resistant bacteria support a differentiated product profile. Potential microbiome-sparing benefits are strategically relevant in CDI, where recurrence and disruption of beneficial gut organisms are important treatment challenges.

Intellectual Property Protection

Long-dated patent coverage and regulatory exclusivity could protect ibezopolstat from direct competition if approved, extending the period available to recover development costs and build commercial value. Broad international coverage also supports potential partnering or regional commercialization strategies.

Bears Say

Pre-revenue Business Model

Acurx has not yet established recurring product revenue, so its financial performance depends on advancing clinical assets rather than operating cash generation. Continued losses leave future value dependent on successful development, regulatory approval, and eventual commercialization or partnering.

Cash Burn And Financing Dependence

Persistent negative cash flow means Acurx is not self-funding its development programs. Management expects to use equity-line drawdowns, equity offerings, partnerships, or grants, creating ongoing financing dependence and potential dilution before meaningful product revenue begins.

Conditional Clinical Execution Path

The next development phase remains contingent on trial results, government funding, and FDA feedback, while the potential PATHFINDER 2 program could involve about 350 patients and 1.5 to 2 years of enrollment. These conditions create substantial execution and timeline uncertainty.

Acurx Pharmaceuticals News

3ZO0 FAQ

What was Acurx Pharmaceuticals’s price range in the past 12 months?
Acurx Pharmaceuticals lowest stock price was €5.09 and its highest was €5.20 in the past 12 months.
What is Acurx Pharmaceuticals’s market cap?
Acurx Pharmaceuticals’s market cap is €5.69M.
When is Acurx Pharmaceuticals’s upcoming earnings report date?
Acurx Pharmaceuticals’s next earnings report is estimated for Mar 18, 2027 (not yet confirmed), which is in 117 days.
How were Acurx Pharmaceuticals’s earnings last quarter?
Acurx Pharmaceuticals released its earnings results on Nov 12, 2026. The company reported -€0.446 earnings per share for the quarter, missing the consensus estimate of -€0.343 by -€0.103.
Is Acurx Pharmaceuticals overvalued?
According to Wall Street analysts Acurx Pharmaceuticals’s price is currently Undervalued.
Does Acurx Pharmaceuticals pay dividends?
Acurx Pharmaceuticals does not currently pay dividends.
What is Acurx Pharmaceuticals’s EPS estimate?
Acurx Pharmaceuticals’s EPS estimate is -0.36.
How many shares outstanding does Acurx Pharmaceuticals have?
Acurx Pharmaceuticals has 6,058,135 shares outstanding.
What happened to Acurx Pharmaceuticals’s price movement after its last earnings report?
Acurx Pharmaceuticals reported an EPS of -€0.446 in its last earnings report, missing expectations of -€0.343. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Acurx Pharmaceuticals?
Currently, no hedge funds are holding shares in DE:3ZO0
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology